• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Bevacizumab injections effective in treating macular neovascularization in myopic patients

Article

Researchers retrospectively analyzed the longitudinal clinical data of 117 eyes of 106 Caucasian patients with high myopia MNV treated with intravitreal bevacizumab injections.

Woman holding spectacles | Image Credit: © Anastassiya - © Anastassiya - stock.adobe.com

The researchers concluded that the positive treatment effect of anti-vascular endothelial growth factor injections lasted for 5 years in this patient population. (Image credit: Adobe Stock/Anastassiya)

Monica Ravenstijn, MD, from the Rotterdam Ophthalmic Institute, Rotterdam Eye Hospital, and the Departments of Epidemiology and Ophthalmology, Erasmus Medical Center, both in Rotterdam, The Netherlands, and colleagues reported that visual improvements that resulted from intravitreal injections of bevacizumab (Avastin, Genentech) administered to treat macular neovascularization (MNV) in myopic patients did not persist and the MNV recurred.1

The researchers retrospectively analyzed the longitudinal clinical data of 117 eyes of 106 Caucasian patients with high myopia MNV treated with intravitreal bevacizumab injections. The patients were followed from the initiation of treatment for up to 12 years. The primary outcome measures were the best-corrected visual acuity (BCVA) changes and the recurrence of myopic MNV.

Long-term outcomes

Ravenstijn reported that the BCVA was a mean of 0.56 ± 0.46 logarithm of the minimal angle of resolution (logMAR)(20/80 Snellen) that improved significantly with the first injection to 0.33 ± 0.33 (20/50 Snellen), a difference that reached significance (P < 0.001).

By 4 years after the first injection, in 86 eyes, the BCVA was 0.55 ± 0.57 (P = 0.30) and was not significantly better than the baseline value. The BCVA decreased to 0.84 ± 0.76 (20/125 Snellen) at the 10-year time point in 27 eyes; MNV-related chorioretinal atrophy developed in 53% of those who completed the 10-year visit.

The cumulative incidence rates of recurrent myopic MNV were 34% at 2 years and 59% at 5 years. The decreases in the BCVA eyes with and without recurrent MNV were similar (P =0.58), according to the investigators.

They also found that patchy chorioretinal atrophy and subfoveal MNVs were associated significantly (P = 0.02 and P=0.048, respectively) with recurrent MNV.

The researchers concluded that the positive treatment effect of anti-vascular endothelial growth factor injections lasted for 5 years in this patient population.

“Lifelong treatment is not necessary for most myopic MNV in that 1 to 10 injections were enough to cause regression of the MNV in 91% of cases. One of two eyes developed a recurrent myopic MNV over time, but recurrences did not worsen the course of the BCVA. Large prospective studies using multimodal imaging are needed to build on these findings and elude biomarkers to optimize treatment and visual outcome,” they concluded.

Reference
1. Ravenstijn M, Klaver CCW, Yzer S. et al. Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in white patients with high myopia. Retina. 2021; 43:444-53; DOI: 10.1097/IAE.0000000000003675Metrics
Related Videos
David A. Berntsen, OD, PhD, FAAO, outlines his presentation on the BLINK 2 study presented at the 2024 ARVO meeting
Dr Brianna Rhue, OD, FAAO, FSLS chat about her upcoming presentation at Vision Expo East 2024
R Tracy Williams, OD, FAAO, tells his favorite stories as a team optometrist for the Chicago Bulls, White Sox
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
Brianna Rhue, OD, FAAO, FSLS
Justin Kwan, OD, FAAO
© 2024 MJH Life Sciences

All rights reserved.